Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 071.35 INR 1.39% Market Closed
Market Cap: 944.3B INR
Have any thoughts about
Lupin Ltd?
Write Note

Net Margin
Lupin Ltd

10.9%
Current
2%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.9%
=
Net Income
22.6B
/
Revenue
208B

Net Margin Across Competitors

Country IN
Market Cap 943.9B INR
Net Margin
11%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
No Stocks Found

Lupin Ltd
Glance View

Market Cap
943.9B INR
Industry
Pharmaceuticals

Lupin Ltd. is a global pharmaceutical powerhouse rooted in Mumbai, India, renowned for its commitment to providing high-quality, affordable medicines across a spectrum of therapeutic areas. Founded in 1968, this rapidly growing company has carved a niche in generics, specialty pharmaceuticals, and biotechnology. With a robust portfolio that includes over 1,500 products across various disciplines, particularly in cardiovascular, CNS, and anti-infective medications, Lupin has established itself as a key player in the global healthcare ecosystem. The company's strategic focus on research and development ensures a steady pipeline of innovative solutions tailored to meet the needs of patients and healthcare providers alike, positioning Lupin as a dynamic leader in the pharmaceutical industry. Driven by a global vision, Lupin operates in over 100 countries and has earned a reputation for excellence through its extensive manufacturing capabilities and adherence to stringent quality standards. The firm’s dedication to expanding its presence in developed markets, particularly in the U.S. and Europe, underscores its ambition to enhance healthcare access worldwide. For investors, Lupin represents an opportunity characterized by solid growth potential, as it continuously invests in R&D, strengthens its market position, and adapts to the evolving landscape of global healthcare. With a commitment to sustainability and a focus on creating value for stakeholders, Lupin Ltd. not only aims to thrive financially but also to enrich the lives of millions through its innovative healthcare solutions.

LUPIN Intrinsic Value
1 418.64 INR
Overvaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.9%
=
Net Income
22.6B
/
Revenue
208B
What is the Net Margin of Lupin Ltd?

Based on Lupin Ltd's most recent financial statements, the company has Net Margin of 10.9%.